Skip to main content

An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients

Hepatology International volume 10, pages 640–646 (2016)Cite this article

Abstract

Purpose

We adopted a new strategy to explore the relationship between the EMT process of CTCs and hepatocellular carcinoma (HCC). Furthermore, we intend to illustrate the potential diagnostic value of CTCs of distinct phenotypes in HCC.

Methods

The clinical data of 33 HCC patients and 10 healthy volunteers were collected retrospectively. By using the optimized CanPatrol CTC enrichment technique, patient blood samples of about 5 ml were collected, and CTCs were identified and characterized. The first step of this detection process was to isolate CTCs via a filter-based method; then, an RNA in situ hybridization (RNA-ISH) technique based on the branched DNA signal amplification technology was used to classify the CTCs according to EMT markers. The relationships between HCC CTCs and clinical characteristics were analyzed.

Results

The number of epithelial CTCs was related to tumor size (r = 0.456, p = 0.008), epithelial-mesenchymal-mixed CTCs were related to tumor number (r = 0.421, p = 0.015), and mesenchymal CTC was associated with metastasis (r = 0.375, p = 0.032). There was no significant correlation between CTC number and other clinicopathological factors, such as age, serum AFP level or cirrhosis.

Conclusions

Epithelial-mesenchymal-mixed CTCs seem to play an important role in EMT transition in HCC, mixed CTCs might be a vital factor for intrahepatic metastasis, and mesenchymal CTCs had the potential to be a predictor of extrahepatic metastasis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Parkin DM, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94(2):153–156

    CAS  Article  PubMed  Google Scholar 

  2. Ferenci P, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44(4):239–245.

    Article  PubMed  Google Scholar 

  3. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31(4):461–476

    CAS  Article  PubMed  Google Scholar 

  4. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4(6):448–456

    CAS  Article  PubMed  Google Scholar 

  5. Imamura H, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38(2):200–207

    Article  PubMed  Google Scholar 

  6. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011;13(6):228

    Article  PubMed  PubMed Central  Google Scholar 

  7. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2(6):442–54.

    CAS  Article  PubMed  Google Scholar 

  8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119(6):1420–1428

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Kalluri R. EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009;119(6):1417–1419

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Osta WA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64(16):5818–5824

    CAS  Article  PubMed  Google Scholar 

  11. Giuliano M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13(3):R67

    Article  PubMed  PubMed Central  Google Scholar 

  12. Larsson A, et al. Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(−/−)Vim(−/−) mice. Neurochem Res 2004;29(11):2069–2073

    CAS  Article  PubMed  Google Scholar 

  13. McInroy L, Maatta A. Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 2007;360(1):109–114

    CAS  Article  PubMed  Google Scholar 

  14. Yu W, Kamara H, Svoboda KK. The role of twist during palate development. Dev Dyn 2008;237(10):2716–2725

    CAS  Article  PubMed  Google Scholar 

  15. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007;253(2):180–204

    CAS  Article  PubMed  Google Scholar 

  16. Weissenstein U, et al. Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer 2012;12:206

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Deng G, et al. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 2008;10(4):R69

    Article  PubMed  PubMed Central  Google Scholar 

  18. Yu M, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339(6119):580–584

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Gorges TM, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012;12:178

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Wu S, et al. Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions. Clin Chem Lab Med (CCLM) 2014;52(2):243–251

    CAS  Article  Google Scholar 

  21. Zhang Y, et al. Circulating tumor cells in hepatocellular carcinoma: detection techniques, clinical implications, and future perspectives. Semin Oncol 2012;39(4):449–460

    CAS  Article  PubMed  Google Scholar 

  22. Talasaz AH, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009;106(10):3970–3975

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Andreopoulou E, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex Cell Search system. Int J Cancer 2012;130(7):1590–1597

    CAS  Article  PubMed  Google Scholar 

  24. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010;2010:617421

    Article  PubMed  Google Scholar 

  25. Sun YF, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013;57(4):1458–1468

    CAS  Article  PubMed  Google Scholar 

  26. Allard WJ, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10(20):6897–6904

    Article  PubMed  Google Scholar 

  27. Cristofanilli M, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420–1430

    Article  PubMed  Google Scholar 

  28. Matthew EM, et al. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget 2016;7(4):3662–3676

    PubMed  Google Scholar 

  29. Mani SA, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133(4):704–715

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. Vesuna F, et al. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 Expression1. Neoplasia 2009;11(12):1318–1328

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

    Affiliations

    1. Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China

      Yong-kang Liu & Li-gong Lu

    2. Department of Interventional Radiology, Cancer Center, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China

      Bao-shan Hu & Zhong-liang Li

    3. Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China

      Xu He & Yong Li

    Authors
    1. Yong-kang Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Bao-shan Hu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Zhong-liang Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Xu He
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yong Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Li-gong Lu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Li-gong Lu.

    Ethics declarations

    Conflict of interest

    Written informed consent was obtained from each patient and volunteer, and the final protocol was approved by the independent ethics committee of Guangdong General Hospital & Guangdong Academy of Medical Sciences. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Li-gong Lu, Yong-kang Liu, Bao-shan Hu, Zhong-liang Li, Xu He and Yong Li declare that they have no conflict of interest.

    Additional information

    Yong-kang Liu, Bao-shan Hu and Zhong-liang Li have contributed equally to this work.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Liu, Yk., Hu, Bs., Li, Zl. et al. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int 10, 640–646 (2016). https://doi.org/10.1007/s12072-016-9732-7

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12072-016-9732-7

    Keywords

    • Hepatocellular carcinoma
    • Circulating tumor cells
    • Epithelial-mesenchymal transition
    • Metastasis